20:07 , Jul 13, 2018 |  BC Week In Review  |  Company News

Regulus reducing headcount by 60%

Regulus Therapeutics Inc. (NASDAQ:RGLS) reduced its headcount by an additional 60% and paused recruitment efforts for its RG-012 clinical program in Alport syndrome to save cash. In May 2017, the company reduced its headcount by...
21:28 , May 24, 2018 |  BC Extra  |  Preclinical News

miRNA-targeted circular single-stranded DNA to treat cancer

A Nankai University-based team developed a small circular single-stranded DNA molecule that inhibits cancer growth in cells and mice by sequestering microRNAs (miRNAs) that silence tumor suppressor genes. Preclinical deals in nucleic acid modalities over the...
02:06 , May 11, 2018 |  BC Innovations  |  Finance

Amplifying oligos

The last five years have seen a steady stream of preclinical deals for antisense, siRNA and mRNA therapies that suggests pharmas are taking the modalities seriously as alternatives to traditional small molecules and antibodies. But...
17:58 , Apr 13, 2018 |  BC Week In Review  |  Company News

AZ gets NASH candidate from Ionis

AstraZeneca plc (LSE:AZN; NYSE:AZN) exercised an option to obtain worldwide rights to non-alcoholic steatohepatitis (NASH) antisense candidate IONIS-AZ6-2.5-LRx (AZD2693) from Ionis Pharmaceuticals Inc. (NASDAQ:IONS). Ionis will receive $30 million from AstraZeneca and is eligible for...
23:29 , Oct 6, 2017 |  BioCentury  |  Finance

High as a Kite

The acquisition of Kite Pharma Inc. by Gilead Sciences Inc. turned what would have been a flattish quarter into another period of outperformance, and relieved the cash constraints that could have prevented specialists from continuing...
16:45 , Jul 11, 2017 |  BC Extra  |  Financial News

Evelo raises $50M in series B round

Evelo Biosciences Inc. (Cambridge, Mass.) raised $50 million in a series B round from Flagship Pioneering; GV, the venture arm of Alphabet Inc. (NASDAQ:GOOG); Celgene Corp. (NASDAQ:CELG); the Mayo Clinic; and Alexandria Venture Investments. Spokesperson...
23:42 , Jun 13, 2017 |  BC Extra  |  Company News

Management tracks

General Electric Co. (NYSE:GE) promoted Kieran Murphy to president and CEO of its GE Healthcare unit. He was president and CEO of GE Healthcare Life Sciences. Murphy succeeds John Flannery, who was named GE's CEO...
00:30 , Jun 9, 2017 |  BC Extra  |  Company News

Management tracks

Neurological diseases play Flex Pharma Inc. (NASDAQ:FLKS) said Christoph Westphal will step down as CEO, effective July 3. He will remain chairman. President of R&D William McVicar will be interim CEO. Cancer company ViraTherapeutics GmbH (Innsbruck,...
00:05 , May 20, 2017 |  BioCentury  |  Strategy

Henri: N of 1

Gaucher’s disease had swollen Brian Berman’s spleen to the size of a basketball and physicians at NIH told the three-year-old’s parents that it had to be removed. It was 1984, there was no effective treatment...
19:56 , May 12, 2017 |  BC Week In Review  |  Company News

Regulus reducing headcount by 30%

Regulus Therapeutics Inc. (NASDAQ:RGLS) said it reduced headcount across the company by about 30% to 65. At Dec. 31, 2016, the company had 97 employees. Regulus said the restructuring will lead to annual savings of...